MapLight Therapeutics, Inc. (MPLT)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
MPLT Chart
People also search for
Maplight Therapeutics' Schizophrenia Drug Hits Phase II Primary Endpoint
Maplight Therapeutics NASDAQ: MPLT reported that its Phase II ZEPHYR trial of ML-007C-MA met its primary endpoint in schizophrenia, with the twice-daily regimen producing a statistically significant improvement in Positive and Negative Syndrome Scale, or PANSS, total scores versus placebo at five weeks.
MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Phase II IRIS Study Results for ML-004 in Autism Spectrum Disorder Transcript
MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Phase II IRIS Study Results for ML-004 in Autism Spectrum Disorder Transcript
MapLight Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 John H. Burbank III Passport Capital LLC | 364,705 | $6.41M | $4.29M | -$2.12M | -33.11% |
 David Kim Paradigm Biocapital Advisors LP | 685,852 | $18.63M | $8.06M | -$10.57M | -56.74% |
 Joseph Castro Nuveen LLC | 17,921 | $322,778.47 | $218,277.78 | -$104,500.69 | -32.38% |
 Ellen York T. Rowe Price Investment Management Inc. | 2.78M | $48.88M | $32.69M | -$16.2M | -33.14% |
 Regan O'Neill Burkehill Global Management LP | 75,000 | $1.32M | $881,250 | -$436,125 | -33.11% |
MapLight Therapeutics, Inc. (MPLT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has MapLight Therapeutics, Inc. ever had a stock split?
MapLight Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Christopher A. Kroeger CEO | NASDAQ (NGS) Exchange | 56565P103 CUSIP |
| US Country | 133 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for patients who suffer from debilitating central nervous system disorders. Incorporated in 2018 and based in Redwood City, California, the company was previously known as Alvarado Therapeutics, Inc. before rebranding in August 2019. MapLight Therapeutics is a subsidiary of Catalyst4, Inc., and it is committed to identifying neural circuits that are causally linked to various diseases, aiming to target these circuits for effective therapeutic modulation.
Products and Services
- ML-007C-MA:
This product is a fixed-dose combination of an M 1 /M 4 muscarinic agonist, designed specifically for the treatment of schizophrenia and psychosis associated with Alzheimer's disease. By targeting specific muscarinic receptors, ML-007C-MA seeks to alleviate symptoms and improve the overall quality of life for affected patients.
- ML-004:
ML-004 is being developed to address social communication deficits and/or irritability in individuals with autism spectrum disorder. This product aims to help patients improve their social interactions and manage irritability, thereby enhancing their everyday experiences and interactions.
- ML-021:
This treatment focuses on alleviating motor deficits in patients suffering from Parkinson’s disease. By addressing the motor symptoms associated with the disease, ML-021 aims to improve the mobility and quality of life for those affected by this challenging condition.
- ML-009:
ML-009 is a G-protein-coupled receptor 52 positive allosteric modulator intended for the treatment of hyperactivity, impulsivity, and agitation-related disorders. This product is designed to refine behavioral symptoms and enhance the stability of patients, providing them with better control over their impulsive behaviors and overall emotional state.
